200
Participants
Start Date
January 25, 2024
Primary Completion Date
January 30, 2025
Study Completion Date
January 30, 2025
LP-003
Liquid in vial
Placebo
Liquid in vial
Omalizumab
Liquid in vial
RECRUITING
Beijing Friendship Hospital, Capital Medical University, Beijing
RECRUITING
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing
RECRUITING
Peking University Third Hospital, Beijing
RECRUITING
The First Affiliated Hospital of China Medical University, Beijing
RECRUITING
The First Hospital of Peking University, Beijing
RECRUITING
The First Affiliated Hospital of PLA Army Medical University, Chongqing
RECRUITING
Fujian Medical University Union Hospital, Fuzhou
RECRUITING
Dermatology Hospital of Southern Medical University, Guangzhou
RECRUITING
The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou
RECRUITING
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan
RECRUITING
The Second XiangYa Hospital of Central South University, Changsha
RECRUITING
Hospital of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing
RECRUITING
Shengjing Hospital of China Medical University, Shenyang
RECRUITING
Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai
RECRUITING
Shanghai Skin Disease Hospital, Shanghai
RECRUITING
the Second Affiliated Hospital of Xi'an Jiaotong University, Xi’an
Lead Sponsor
Longbio Pharma
INDUSTRY